Home › Linfoma diffuso a grandi cellule B › Tennessee › Nashville
Studi clinici su Linfoma diffuso a grandi cellule B a Nashville, TN
15 studi su Linfoma diffuso a grandi cellule B cercano partecipanti presso sedi a Nashville e dintorni (entro circa 30 miglia). Apri uno studio per vedere chi può partecipare e come contattare il team.
Testo ufficiale dello studio (inglese)
Stai reclutando per uno studio? Mettilo in evidenza in cima alla pagina — $99 per 30 giorni →
Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL
In reclutamentoFase 2
- Vanderbilt University Medical Center, Nashville
Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma
In reclutamentoFase 2
- Vanderbilt University/Ingram Cancer Center, Nashville
A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies
In reclutamentoFase 1/2
- Tennessee Oncology, Pllc Nashville, Nashville
A Clinical Study of MK-1045 in People With Non-Hodgkin Lymphoma (MK-1045-008)
In reclutamentoFase 1/2
- SCRI Oncology Partners ( Site 0100), Nashville
A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)
In reclutamentoFase 2
- SCRI Oncology Partners ( Site 7002), Nashville
A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
In reclutamentoFase 1
- Sarah Cannon Research Institute, Nashville
- Vanderbilt University Medical Center, Nashville
A Study of LY4152199 in Participants With Previously Treated B-cell Malignancies (BAF_FRontier-1 )
In reclutamentoFase 1
- SCRI Oncology Partners, Nashville
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
In reclutamentoFase 1
- Scri Oncology Partners, Nashville
- Vanderbilt Medical Center, Nashville
Evaluate Optimization of CRS Profile for Glofit Monotherapy and Glofit+GemOx in R/R Aggressive B-NHL
In reclutamentoFase 2
- Tennessee Oncology, Nashville
Study of Allo-QuadCAR01-T, an Allogeneic CAR-T Targeting CD19/CD20, in Patients With Relapsed or Refractory B-Cell Malignancies
In reclutamentoFase 1/2
- Sarah Cannon Research Institute, Nashville
Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma
In reclutamentoFase 1/2
- Vanderbilt University Medical Center, Nashville
Gene Therapy for CD19-Positive Hematologic Malignancies (SENTRY-CD19)
In reclutamentoFase 1/2
- TriStar BMT, Nashville
A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
In reclutamentoFase 3
- SCRI Oncology Partners, Nashville
DALY II USA/ MB-CART2019.1 for DLBCL
In reclutamentoFase 2
- SCRI Oncology Partners, Nashville
A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies
In reclutamentoFase 1
- Tennessee Oncology, Nashville
Studi su Linfoma diffuso a grandi cellule B in altre città
- New York City, NY21 studi
- Baldwin Park, CA19 studi
- Chicago, IL18 studi
- Houston, TX17 studi
- Los Angeles, CA17 studi
- Boston, MA16 studi
- Milwaukee, WI16 studi
- Portland, OR15 studi
- Philadelphia, PA15 studi
- Durham, NC14 studi
- Dallas, TX13 studi
- Seattle, WA12 studi
Altri studi a Nashville
- Cancro del polmone non a piccole cellule97 studi
- Cancro al seno80 studi
- Cancro metastatico70 studi
- Cancro colorettale69 studi
- Cancro (tutti i tipi)65 studi
- Cancro ovarico49 studi
- Cancro alla prostata42 studi
- Cancro ai polmoni40 studi
- Carcinoma a cellule squamose della testa e del collo39 studi
- Cancro pancreatico39 studi
- Cancro dell'endometrio38 studi
- Melanoma33 studi
Fonte: ClinicalTrials.gov, dati recuperati il 5 ott 2026. Ogni studio stabilisce i propri criteri di idoneità; è il team di ricerca a decidere chi può partecipare.